Clinical trial · Observational
Myeloproliferative Neoplasms (MPNs) Patient Registry
Clinical and Molecular Epidemiology of Myeloproliferative Neoplasms (MPNs)
NCT02760238CI-TRIAL-00080236recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.
Conditions
Conditions (10)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Eosinophilic Leukemia-not Otherwise Specified | Chronic Eosinophilic Leukemia, Not Otherwise Specified | ONTOLOGY_EXACT | 0.98 |
| Essential Thrombocythemia | Essential Thrombocythemia | ONTOLOGY_EXACT | 0.98 |
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Leukemia, Myelomonocytic, Chronic | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Leukemia, Myelomonocytic, Juvenile | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Mastocytosis | Mastocytosis | ONTOLOGY_EXACT | 0.98 |
| Myelodysplastic-Myeloproliferative Diseases | Myelodysplastic/Myeloproliferative Neoplasm | ALIAS | 0.90 |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Polycythemia Vera |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observational | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with a diagnosis of MPN
- description
- Patients with a myeloproliferative neoplasm (MPN) diagnosis: Atypical chronic myeloid leukemia (aCML), chronic eosinophilic leukemia-not otherwise specified (CEL NOS), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), essential thrombocythemia (ET), JMML, mastocytosis, MPN unclassifiable, myeloproliferative neoplasm/myelodysplastic syndrome unclassifiable (MPN/MDS unclassifiable), primary myelofibrosis (PMF), post-ET MF, post-PV MF, or (refractory anemia with ringed sideroblasts associated with marked thrombocytosis) RARS-T
- interventionNames
- Other: Observational
Primary outcomes (1)
- measure
- Survival
- timeFrame
- Annually or at the time of transformation of disease, up to 10 years
- description
- Survival of patients with MPN
Secondary outcomes (16)
- measure
- General patient characteristics will be captured from the Hematologic Malignancy tissue bank
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: Diagnosis of one of the following myeloproliferative neoplasms (MPNs): * Atypical CML (aCML) * Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS), * Chronic myelomonocytic leukemia (CMML) * Chronic neutrophilic leukemia (CNL), * Essential thrombocythemia (ET), * Juvenile myelomonocytic leukemia (JMML), * Mastocytosis, MPN unclassifiable * MPN/MDS unclassifiable, * Primary myelofibrosis (PMF), * Post-essential thrombocythemia myelofibrosis (post-ET MF), * Post-polycythemia vera MF (post-PV MF) * Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.